Xtl Biopharmaceuticals LTD XTLB
We take great care to ensure that the data presented and summarized in this overview for XTL BIOPHARMACEUTICALS LTD is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XTLB
View all-
Noked Capital LTD Tel Aviv, L3199KShares$336,1200.02% of portfolio
-
Noked Israel LTD Ramat Hasharon, L3199KShares$336,1200.1% of portfolio
-
Morgan Stanley New York, NY26.5KShares$44,7020.0% of portfolio
-
Rhumbline Advisers Boston, MA11KShares$18,5120.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
Latest Institutional Activity in XTLB
Top Purchases
Top Sells
About XTLB
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Insider Transactions at XTLB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|